Literature DB >> 3111619

Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.

W H Matta, R W Shaw, R Hesp, D Katz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3111619      PMCID： PMC1246674          DOI： 10.1136/bmj.294.6586.1523

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  5 in total

1.  Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist.

Authors:  D L Healy; H M Fraser; S L Lawson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-10

2.  Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy.

Authors:  H K Genant; C E Cann; B Ettinger; G S Gordan
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

3.  Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis.

Authors:  R W Shaw; H M Fraser; H Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-03

4.  Precise measurement of vertebral mineral content using computed tomography.

Authors:  C E Cann; H K Genant
Journal:  J Comput Assist Tomogr       Date:  1980-08       Impact factor: 1.826

5.  Measurement of bone mineral content (BMC) of the lumbar spine, I. Theory and application of a new two-dimensional dual-photon attenuation method.

Authors:  B Krølner; S Pors Nielsen
Journal:  Scand J Clin Lab Invest       Date:  1980       Impact factor: 1.713
  5 in total
  10 in total

Review 1.  Bone mineral density levels in elite female athletes.

Authors:  R L Wolman
Journal:  Ann Rheum Dis       Date:  1990-12       Impact factor: 19.103

Review 2.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat.

Authors:  A Goulding; E Gold
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

4.  Transdermal oestrogene application a contraindication in therapy of endometriosis with gonadotropin-releasing hormone analogues.

Authors:  A Rosen; M Klein; A Beck
Journal:  Klin Wochenschr       Date:  1990-05-17

Review 5.  Gonadotrophin releasing hormone analogues for gynaecological disorders and infertility.

Authors:  H M Fraser; J Waxman
Journal:  BMJ       Date:  1989-02-25

Review 6.  Medical management of fibroids.

Authors:  D T Baird; C P West
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-18

Review 7.  A benefit-risk assessment of medical treatment for uterine leiomyomas.

Authors:  Vincenzo De Leo; Giuseppe Morgante; Antonio La Marca; Maria Concetta Musacchio; Massimo Sorace; Chiara Cavicchioli; Felice Petraglia
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; P Morosini; R De Pirro
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

9.  Total and regional bone mineral content in women treated with GnRH agonists.

Authors:  H Rico; F Arnanz; M Revilla; S Perera; M Iritia; L F Villa; I Arribas
Journal:  Calcif Tissue Int       Date:  1993-05       Impact factor: 4.333

10.  Autoimmune progesterone dermatitis in a patient with endometriosis: case report and review of the literature.

Authors:  Alan P Baptist; James L Baldwin
Journal:  Clin Mol Allergy       Date:  2004-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.